Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNF&#945; therapy in inflammatory bowel disease patients: a report from the epi-IIRN.

Gorelik, Yuri; Freilich, Shay; Gerassy-Vainberg, Shiran; Pressman, Sigal; Friss, Chagit; Blatt, Alexandera; Focht, Gili; Weisband, Yiska Loewenberg; Greenfeld, Shira; Kariv, Revital; Lederman, Nathan; Dotan, Iris; Geva-Zatorsky, Naama; Shen-Orr, Shai Shlomo; Kashi, Yechezkel; Chowers, Yehuda

Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN.

Gorelik, Yuri; Freilich, Shay; Gerassy-Vainberg, Shiran; Pressman, Sigal; Friss, Chagit; Blatt, Alexandera; Focht, Gili; Weisband, Yiska Loewenberg; Greenfeld, Shira; Kariv, Revital; Lederman, Nathan; Dotan, Iris; Geva-Zatorsky, Naama; Shen-Orr, Shai Shlomo; Kashi, Yechezkel; Chowers, Yehuda.

Afiliação

Gorelik Y; Gastroenterology, Rambam Health Care Campus, Haifa, Israel.
Freilich S; Faculty of Biotechnology and Food Engineering, Technion Israel Institute of Technology, Haifa, Israel.
Gerassy-Vainberg S; Clinical Research Institute, Rambam Health Care Campus, Haifa, Israel.
Pressman S; Clinical Research Institute, Rambam Health Care Campus, Haifa, Israel.
Friss C; Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Blatt A; Gastroenterology, Rambam Health Care Campus, Haifa, Israel.
Focht G; Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, The Hebrew University of Jerusalem, Jerusalem, Israel.
Weisband YL; Gastroenterology, Rambam Health Care Campus, Haifa, Israel.
Greenfeld S; The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel.
Kariv R; Innovation Division, Clalit Research Institute, Tel Aviv, Israel.
Lederman N; Medical Informatics, Maccabi Health Services, Tel Aviv, Israel.
Dotan I; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Geva-Zatorsky N; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shen-Orr SS; Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Kashi Y; Gastroenterology, Meuhedet Health Services, Jerusalem, Israel.
Chowers Y; Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.

Gut ; 71(2): 287-295, 2022 02.

Article em En | MEDLINE | ID: mdl-34344783

Assuntos

Adalimumab/imunologia; Antibacterianos/uso terapêutico; Formação de Anticorpos/efeitos dos fármacos; Doenças Inflamatórias Intestinais/tratamento farmacológico; Infliximab/imunologia; Inibidores do Fator de Necrose Tumoral/imunologia; Adalimumab/uso terapêutico; Adulto; Animais; Feminino; Humanos; Doenças Inflamatórias Intestinais/imunologia; Doenças Inflamatórias Intestinais/mortalidade; Infliximab/uso terapêutico; Israel; Masculino; Camundongos; Camundongos Endogâmicos C57BL; Pessoa de Meia-Idade; Sistema de Registros; Análise de Sobrevida; Inibidores do Fator de Necrose Tumoral/uso terapêutico; Adulto Jovem

Palavras-chave

TNF-alpha; antibiotics; inflammatory bowel disease; infliximab; intestinal microbiology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Adalimumab / Infliximab / Inibidores do Fator de Necrose Tumoral / Antibacterianos / Formação de Anticorpos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google